Galat A, Lane WS, Standaert RF, Schreiber SL. A rapamycin-selective 25-kDa immunophilin. Biochemistry. 1992;31(8):2427-34.
Hung DT, Schreiber SL. cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. Biochem Biophys Res Commun. 1992;184(2):733-8.
Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science. 1992;256(5061):1315-8.
Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem. 1993;268(30):22825-9.
Albers MW, Brown EJ, Tanaka A, Williams RT, Hall FL, Schreiber SL. An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells. Ann N Y Acad Sci. 1993;696:54-62.
Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat Chem Biol. 2007;3(6):331-8. doi:10.1038/nchembio883
Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-8. doi:10.1038/369756a0
Floto A, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy. 2007;3(6):620-2.
Schreiber SL, Crabtree GR. Immunophilins, ligands, and the control of signal transduction. Harvey Lect. 1995;91:99-114.
Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-30.